临床试验/NCT05029635

NCT05029635已完成3 期

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults (ESLIM-01 Study)

Hutchmed37 个研究点分布在 1 个国家目标入组 272 人开始时间: 2021年10月27日最近更新: 2026年5月4日

适应症

干预措施

试验速览

阶段: 3 期
状态: 已完成
发起方
入组人数: 272
试验地点: 37
主要终点: the durable response rate in the primary study

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

The purpose of this study is to determine whether HMPL-523 (sovleplenib) is safe and effective in the treatment of chronic Immune Thrombocytopenic Purpura (ITP).

详细描述

This study consists of a double-blind phase (primary study) followed by an open-label phase (sub-study). The double-blind phase(n=188) is a randomized, double-blind, placebo-controlled phase III clinical trial in adult patients with primary ITP to determine whether HMPL-523 (sovleplenib) is safe and effective in the treatment of chronic ITP. The sub-study provides open-label HMPL-523 treatment to assess long-term safety and efficacy. The open-label phase have Cohort1 and Cohort 2. Cohort 1 enrolled patients from primary study who have received double-blind study treatment for 12 weeks with sustained platelet count <50×10⁹/L or have received double-blind study treatment for 24 weeks. Cohort 2 enrolled primary ITP patients(n=84) with disease duration >3 months.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•for double-blind phase:
•Voluntary signature of written informed consent form;
•Male or female aged 18~75 years;
•Performance Status score [Eastern Cooperative Oncology Group (ECOG) score] 0~1;
•Having been diagnosed as ITP prior to randomization, and duration of disease is more than 6 months;
•Intolerance or insufficient response, or recurrence after at least one anti-ITP standard drug therapy;
•Patients must have a history of response to previous ITP therapy;
•One combined anti-ITP therapy is allowed in this study, however, the following criteria need to be met:
•The dose of glucocorticoid has been stable for 4 weeks prior to randomization (<20 mg Prednisone equivalent);
•The dose of Danazol has been stable for 3 months prior to randomization;
•The dose of immunosuppressant (only including Azathioprine, Ciclosporin A, Mycophenolate mofetil) has been stable for 3 months prior to randomization.
•The condition is relatively stable; WHO bleeding scale grade is 0-1; no emergency treatment is expected within 2 weeks as judged by investigators.
•The laboratory examinations need to meet the following conditions (no treatment for this abnormal variable is given within one week prior to blood collection):
•Average platelet count <30×10^9 /L (and none > 35×10^9 /L unless as a result of rescue therapy) from at least 3 qualifying counts;
•Hemoglobin ≥100 g/L, neutrophil count >1.5×10^9/L;
•Total bilirubin (TBIL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×upper limit of normal (ULN);
•Serum creatinine concentration ≤1.5×ULN and creatinine clearance ≥50 mL/min;
•Serum amylase and lipase ≤1.5×ULN;
•International normalized ratio (INR), activated partial thromboplastin time (APTT) not exceeding 20% of normal range.
•Male or female patients of childbearing potential must agree to use effective contraceptive methods during the study and within 90 days after last dose of study drug, e.g., double barrier contraceptive method, condom, oral or injectable contraceptives, intrauterine device, etc. Postmenopausal women (>50 years old and no menses for >1 year) and surgically sterilized women are not subject to this condition.

排除标准

•for double-blind phase:
•Evidence on the presence of secondary causes of immune thrombocytopenia;
•Clinically serious hemorrhage requiring immediate adjustment of platelet (e.g., hypermenorrhea with significantly decreased hemoglobin);
•Clinically symptomatic gastrointestinal hemorrhage within 6 months prior to screening visit (e.g., haematemesis, tarry stool, however, the positive occult blood test without any sign or symptom of gastrointestinal hemorrhage will not be considered as "clinically symptomatic", or hemorrhoids hemorrhage is one exception);
•known history of vital organ transplantation or hematopoietic stem cell / bone marrow transplantation;
•Has received live vaccine within 8 weeks prior to Day 1 (baseline visit); or plan for immunization with live vaccine during the study;
•Splenectomy within 12 weeks prior to randomization;
•Major surgery within 4 weeks prior to the randomization, or plan for major elective surgery during the study;
•Previous history of malignant tumors (except for the basal cell carcinoma of skin or cervical carcinoma in situ that have been cured);
•History of important arterial / venous embolic disease;
•Intracranial hemorrhage within 6 months before screening visit;
•History of serious cardiovascular disease (e.g., grade III/IV congestive heart failure, arrhythmia or angina pectoris requiring drug therapy, unstable angina pectoris, intracoronary stent implantation, angioplasty or coronary artery bypass grafting, or QTc ≥450 ms);
•Hypertension that can not be controlled with drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);
•Previous history of serious gastrointestinal disease, such as dysphagia, active gastric ulcer, inability to take drugs orally or absorption disorder for oral drugs;
•Human immunodeficiency virus (HIV) infection, or hepatitis B (in case of positive HBsAg or HBcAb, positive HBV DNA needs to be determined), or hepatitis C (positive HCV RNA), or liver cirrhosis;
•Significant active infection that is not controlled clinically (e.g., sepsis, pneumonia or abscess), or serious infection within 6 weeks prior to randomization (leading to hospitalization or requiring treatment with antibiotic injections);
•Has received rescue therapy for ITP within 2 weeks prior to randomization; Has received the treatment for the objective of increasing platelet within 4 weeks prior to randomization (including but not limited to glucocorticoid, thrombopoietin, thrombopoietin receptor agonist, Cyclosporine A, Mycophenolate mofetil, etc.), except those meeting the inclusion criterion 7;
•Having received Rituximab within 14 weeks prior to randomization;
•Having received traditional Chinese medicine within 1 week prior to randomization;
•Requiring long-term/continuous use of the drugs that may affect platelet function [including but not limited to aspirin, Clopidogrel, ticagrelor, NSAIDs, etc.], or anticoagulants;
•Intake of potent CYP3A inhibitor or inducer, as well as sensitive or narrow therapeutic window substrates of CYP3A, CYP1A2 or CYP2B6 two weeks (three weeks for Hypericum perforatum) or 5 half-lives prior to randomization (whichever is longer);
•Having participated in the clinical study for drugs or invasive medical device 4 weeks prior to randomization (or within 5 half-lives of the study drug prior to randomization, whichever is longer);
•Having received spleen tyrosine kinase Syk inhibitor (e.g., Fostamatinib) previously;
•Known allergy to the active ingredient or excipient of study drug;
•Presence of serious psychological or mental disorder;
•Alcoholic or drug abuser;
•Female patients in pregnancy or breast feeding;
•Being unsuitable to participate in this study, as considered by investigators.
•Inclusion Criteria for open label phase:
•Voluntary signing of the ICF for the sub-study;
•Performance status score (ECOG score) 0-1;
•Relatively stable disease, WHO bleeding grade 0-1;
•Female patients of childbearing potential must agree to use highly effective treatment of contraception from screening until 30 days after discontinuation of study treatment of;
•Male patients with fertile female partners must consent to use barrier contraception during the study period and for 30 days after the termination of study treatment.
•Exclusion Criteria for open label phase:
•History of significant arterial/venous embolic disease;
•History of serious cardiovascular disease；
•Hypertension uncontrolled by medications；
•Known hypersensitivity to the active ingredient or excipients of the study drug;
•Patients with severe psychological or mental disorders;
•Alcoholics or drug abusers;
•Female patients who are pregnant and lactating;
•Patients who, in the opinion of the investigator, are not suitable for this study.

研究组 & 干预措施

Drug: placebo

Placebo Comparator

Primacy study (Randomized, Double-Blind Phase): Eligible subjects will receive 300 mg HMPL-523 matched placebo treatment once daily for 24 weeks.

干预措施: Placebo (Drug)

Drug: HMPL-523

Active Comparator

Primacy study (Randomized, Double-Blind Phase): Eligible subjects receive 300 mg HMPL-523 treatment once daily for 24 weeks.

Sub study (Open-label Phase): Eligible subjects receive 300 mg HMPL-523 treatment once daily for 76 weeks after the enrollment of the last patient enrolled in open-label phase.

干预措施: HMPL-523 (Drug)

结局指标

主要结局

the durable response rate in the primary study

时间窗: treatment period Week14-Week24

Platelet count ≥50×10\^9 /L on at least 4 of 6 scheduled visits of Week14-Week24 in the primary study

次要结局

Incidence of treatment emergent adverse events(treatment period Week1-Week24 in the primary study)
the overall response rate in the primary study(treatment period Week1-Week24 in the primary study)
Plasma concentration at steady state 2 hours post dose (C2h,ss)(treatment period Week1-Week24 in the primary study)
Plasma concentration at steady-state trough concentration (Cmin,ss)(treatment period Week1-Week24 in the primary study)
Plasma concentration at steady state 2 hours post dose (C4h,ss)(treatment period Week1-Week24 in the primary study)

研究者

发起方

Hutchmed

申办方类型

Industry

责任方

Sponsor

研究点 (37)

Loading locations...

相似试验

已完成

2 期

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic ObesityHypothalamic Obesity

NCT06046443Rhythm Pharmaceuticals, Inc.28

进行中（未招募）

2 期

HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaWarm Antibody Autoimmune Hemolytic Anemia

NCT05535933Hutchmed111

终止

1 期

Safety Study of HPP593 in Subjects During and After Limb ImmobilizationMuscle AtrophyHypodynamia

NCT01524406High Point Pharmaceuticals, LLC.24

终止

1 期

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

NCT03779113Hutchmed69

Unknown

1 期

A Study of HMPL-523 in Relapsed or Refractory Hematologic MalignanciesHematologic Malignancies

NCT02503033Hutchison Medipharma Limited78